Abstract Development of tau-based therapies for Alzheimer’s disease requires an understanding
of the timing of disease-related changes in tau. We quantified the phosphorylation state …

Objective Detection of focal brain tau deposition during life could greatly facilitate accurate
diagnosis of Alzheimer disease (AD), staging and monitoring of disease progression, and …

Importance Positron emission tomography (PET) imaging now allows in vivo visualization of
both neuropathologic hallmarks of Alzheimer disease (AD): amyloid-β (Aβ) plaques and tau …

The endogenous cannabinoid (eCB) system represents a major therapeutic target for the
treatment of a variety of anxiety-related disorders. A recent study has demonstrated that …

Neurofilament light chain (NfL) is a promising fluid biomarker of disease progression for
various cerebral proteopathies. Here we leverage the unique characteristics of the Dominantly …

Alzheimer’s disease (AD) is the most prevalent cause of dementia 1 . Although there is no
effective treatment for AD, passive immunotherapy with monoclonal antibodies against …

Background Models of Alzheimer's disease propose a sequence of amyloid β (Aβ) accumulation,
hypometabolism, and structural decline that precedes the onset of clinical dementia. …

Alzheimer’s disease (AD) pathology develops many years before the onset of cognitive
symptoms. Two pathological processes—aggregation of the amyloid-β (Aβ) peptide into plaques …

Macrophages are important players in the maintenance of tissue homeostasis 1 .
Perivascular and leptomeningeal macrophages reside near the central nervous system (CNS) …

Brain-derived neurotrophic factor (BDNF) acting through the tyrosine kinase B receptor (TrkB)
is thought to be a critical mediator of learning. As there are no available selective …